好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Safety and Tolerability of Selisistat for the Treatment of Huntington's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial
Movement Disorders
(-)
004
Authors/Disclosures
Ralf Reilmann, MD, FAAN (George-Huntington-Institute)
PRESENTER 		The institution of Dr. Reilmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. The institution of Dr. Reilmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for uniQure. The institution of Dr. Reilmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for WAVE. Dr. Reilmann has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WAVE. The institution of Dr. Reilmann has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for IOS-Press. The institution of Dr. Reilmann has received research support from European Union. Dr. Reilmann has a non-compensated relationship as a Executive Committee Member with Huntington Study Group that is relevant to AAN interests or activities. Dr. Reilmann has a non-compensated relationship as a Member of Executive Committee with European Huntington Disease Network that is relevant to AAN interests or activities. Dr. Reilmann has a non-compensated relationship as a Co-Chair Task Force on Huntington Disease with Movement Disorders Socitey that is relevant to AAN interests or activities.
Ferdinando Squitieri, MD, PhD (IRCC Neuromed) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Sarah J. Tabrizi, MD, PhD Sarah J. Tabrizi, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for F. Hoffmann-La Roche Ltd. Sarah J. Tabrizi, MD, PhD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech.
No disclosure on file
No disclosure on file
No disclosure on file
Anne Rosser Anne Rosser has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
David F. Fischer, PhD No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Bernhard G. Landwehrmeyer, MD (Ulm University Hospital) Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ACADIA PHARMACEUTICALS INC, San Diego, CA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck Valby, Denmark. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AOP Orphan Pharmaceuticals AG, Vienna, Austria. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Remix Therapeutics, Inc., Cambridge, MA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for HSG Clinical Research, Inc. Dr. Landwehrmeyer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for F. Hoffmann-La Roche Ltd, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharma AG, Grenzach/Whylen, Germany. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Pharma AG, Basel, Switzerland. The institution of Dr. Landwehrmeyer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Pharma AG, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics, Inc., South Plainfield, NJ . Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Triplet Therapeutics, Inc. Cambridge, MA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda Pharma. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Pharma AG, Grenzach/Whylen, Germany. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for F. Hoffmann-La Roche Ltd, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharma AG, Basel, Switzerland. The institution of Dr. Landwehrmeyer has received research support from CHDI Foundation. The institution of Dr. Landwehrmeyer has received research support from European Commission. The institution of Dr. Landwehrmeyer has received research support from German Federal Government BMBF. The institution of Dr. Landwehrmeyer has received research support from German Research Council DFG. Dr. Landwehrmeyer has received publishing royalties from a publication relating to health care. Dr. Landwehrmeyer has received publishing royalties from a publication relating to health care.
No disclosure on file